Nicrosini F, Pasotti C
Minerva Med. 1983 May 19;74(21):1297-300.
The aim of this research was to evaluate the effectiveness and the tolerability of flutonidin: a new clonidine-like antihypertensive compound. 30 patients (9 man and 21 women, mean age 60.5), affected by mild-moderate essential hypertension, have been randomized in two homogeneous groups of 15 patients, and treated respectively with flutonidin (F) 2 mg/day and clonidine (C) 0.3 mg/day for a period of 15 days at the Hospital. We obtained 60% normalization of blood pressure values in patients of group F and 66% in the patients of group C. The treatment continued after discharge from Hospital at the same doses for a six months period in the 9 normalized patients of group F and in the 10 normalized patients of group C. The results showed an increase of the blood pressure mean values in both groups. Our data seem to indicate that: 1) Flutonidin and clonidine have comparable antihypertensive effect. 2) A partial loss of activity has been observed for both drugs. This phenomenon has been already noted in long-term treatment with clonidine. 3) The tolerability of two compounds resulted satisfactory.
本研究的目的是评估氟托立定(一种新型可乐定样抗高血压化合物)的有效性和耐受性。30例轻中度原发性高血压患者(9例男性,21例女性,平均年龄60.5岁)被随机分为两组,每组15例,并分别在医院接受为期15天的治疗,一组服用2mg/天的氟托立定(F),另一组服用0.3mg/天的可乐定(C)。我们发现F组患者血压值正常化比例为60%,C组为66%。出院后,F组9例血压正常化患者和C组10例血压正常化患者继续以相同剂量治疗6个月。结果显示两组血压平均值均升高。我们的数据似乎表明:1)氟托立定和可乐定具有相当的抗高血压作用。2)两种药物均观察到部分活性丧失。这种现象在可乐定的长期治疗中已有报道。3)两种化合物的耐受性均令人满意。